News

uMotif – first new validated eCOA/ePRO innovation since paper instruments deployed on smartphones

uMotif experts to discuss the eCOA/ePRO market – what’s working, what’s wrong, and what patients need now

uMotif expands leadership team to support growth in US and EU markets

uMotif and ClinOne unify eCOA / ePRO and eConsent

$25.5m of new investment from Athyrium Capital Management fund

Achieving more meaningful patient engagement in rare disease trials

AbbVie and uMotif support rheumatoid arthritis patients with BYOD approach

uMotif collaborates with The University of Manchester on body mapping tool

uMotif evolves leadership team with appointment of Steve Rosenberg as CEO